Fast influenza vaccine production
Based on Redbiotec’s rePAX® technology influenza VLP vaccine candidates were [...]
Geneart Founder at Redbiotec
Redbiotec AG announces today the appointment of Prof. Dr. Ralf [...]
Swiss Economic Forum labels Redbiotec as High Potential SME
We are pleased to announce that Redbiotec has been labeled [...]
New agreement with Roche
Redbiotec AG has signed a new agreement with Roche Diagnostics [...]
Successful proof of concept study with Intercell AG
Intercell and Redbiotec have successfully completed the proof of concept [...]
Growing interest in Redbiotec’s CMV program
Redbiotec has been selected to present its CMV Vaccine program [...]
Redbiotec extends deal with Merck
Redbiotec is pleased to announce that the project started with [...]
Redbiotec closes initial agreement in the field of prime-boost
Redbiotec today announced that it has closed an agreement with [...]
New deal with antibody company
Redbiotec today announced that it has closed a new collaboration [...]
Challenge experiments successfully finalized
The challenge experiment using Redbiotec’s tetravalent influenza VLPs was successfully [...]